SCHEDULE: Bigger Capital Divests Entire Protagenic Therapeutics Stake
Amendment to Schedule 13G
Bigger Capital Fund, LP and its affiliates have reported a complete divestment of their beneficial ownership in Protagenic Therapeutics, Inc., now holding 0% of common stock.
Summary
- Bigger Capital Fund, LP, Bigger Capital Fund GP, LLC, and Michael Bigger (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
- As of August 22, 2025, the Reporting Persons beneficially own 0.00 shares of Protagenic Therapeutics, Inc. common stock.
- This represents 0% of the class of securities.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 3
Explanation: The complete divestment by an institutional investor is generally a negative signal, indicating a lack of confidence in the company's future performance or strategy from that specific investor's perspective.
Negatives
- A significant institutional investor group, Bigger Capital, has fully divested its position in Protagenic Therapeutics, Inc.
- This complete divestment could signal a lack of confidence in the company's future prospects by the Reporting Persons.
Risks
- Potential negative market perception due to the complete divestment by a previously invested entity.
- Loss of a significant shareholder, which could impact liquidity or investor sentiment.
Stakeholder Impact
- Shareholders may interpret the complete divestment by Bigger Capital as a negative signal, potentially leading to decreased investor confidence and selling pressure on the stock.
- Company management could face questions regarding the reasons for the investor's exit and its implications for future capital attraction.
Key Dates
| Date | Description |
|---|---|
| 08/22/2025 | Date of event which requires filing of this statement (beneficial ownership dropped to 0%). |
| 08/25/2025 | Date of signing and filing of the Schedule 13G Amendment No. 1. |
Recommendation
sellThe complete divestment by an institutional investor, as reported in this Schedule 13G Amendment, typically signals a loss of confidence in the company's prospects. While not a direct financial statement, such a move by a significant holder can exert downward pressure on the stock price and warrants a cautious or negative outlook for current and potential investors.
Keywords
Protagenic Therapeutics, Bigger Capital, Schedule 13G, Beneficial Ownership, Divestment, Common Stock, SEC Filing, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.